Efficacy and Safety of Ultra-Rapid Lispro in Younger and Older Patients with Type 2 Diabetes: Randomized Double-Blind PRONTO-T2D Study

INTRODUCTION: Ultra-rapid lispro (URLi) is a new prandial insulin lispro formulation. In the PRONTO-T2D study, URLi, in a basal-bolus regimen with glargine or degludec, was non-inferior to lispro (Humalog(®)) for HbA1c reduction and superior for postprandial glucose (PPG) control. We evaluated the e...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qianyi, Chigutsa, Farai, Chang, Annette M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309112/
https://www.ncbi.nlm.nih.gov/pubmed/35781789
http://dx.doi.org/10.1007/s13300-022-01290-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309112/
https://www.ncbi.nlm.nih.gov/pubmed/35781789
http://dx.doi.org/10.1007/s13300-022-01290-4

Ejemplares similares